New esearch suggests semaglutide may reduce asthma attacks by nearly 40% and COPD flare-ups by 20%, though experts urge caution before drawing conclusions.
Semaglutide, the active substance in Ozempic and Wegovy, is believed to be associated with a nearly 40% decrease in asthma attacks, according to a study involving more than 80,000 British patients.